Nebius Stock: Four New Sites Go Live, but the Real Test Is Whether 2027 Revenue Actually Arrives
Published on 11/18/2026 at 08:11 | Editorial boerse-global.deNebius gave investors two pieces of news this week that pull in opposite directions. Four new data center sites across the US and Europe have started generating revenue, the company said on November 12, and additional capacity came online in New Jersey during the third quarter and into November. The shares responded by climbing 7.3% in pre-market trading to €103.36.
Yet the same shareholder letter that flagged the new sites also confirmed that third-party capacity delays have pushed a slice of expected revenue into 2027. That single sentence now sits at the center of the investment case, and it explains why analysts are pulling in their price targets even as they keep their buy ratings.
The quarter was spectacular — and that is not the question
Revenue for the third quarter of 2026 came in at $980.8 million, a 571% increase year over year. The figure is striking, but it describes what has already happened. What matters more is how reliably the next stage of expansion converts into reported sales, and on that front the company has given itself a narrower runway: management now guides full-year 2026 revenue to the low end of its $3.0 billion to $3.4 billion range.
The distinction investors have to draw is between a timing shift and a permanent shortfall. If the delayed capacity becomes available and the expected revenue follows, the weaker near-term outlook is a deferral, not a broken thesis. If delays repeat, the credibility of the whole plan deserves a harder look.
Should investors sell immediately? Or is it worth buying Nebius?
Capex is climbing faster than confidence
Against that backdrop, the spending plan has become the risk side of the ledger. Nebius raised its 2026 capital expenditure forecast to roughly $27 billion. For 2027, it expects outlays of between $40 billion and $45 billion.
The combination is what makes the calendar so important. Higher spending on its own is manageable if revenue arrives on schedule. The uncomfortable scenario is one where rising outlays coincide with repeated slippage — expectations for future business climb while the operating proof stays missing.
Two banks, two very different messages
Wall Street's response captures the tension. Citigroup's Tyler Radke cut his price target on Monday from $265 to $215 while maintaining a buy recommendation, according to media reports. Bank of America likewise held to its buy rating.
D.A. Davidson offered the more cautious read. Analyst Gil Luria halved his target from $250 to $125 on Friday, keeping a neutral rating. That call does not invalidate the growth potential, but it does show how wide the range of opinion has become: the debate is over how much trust to place in revenue that has been promised for later.
Nebius at a turning point? This analysis reveals what investors need to know now.
What would settle the argument
A constructive case remains available. Should the deferrals stay contained and Nebius meet its adjusted guidance, the strong third quarter would look like evidence for riding out short-term noise rather than a warning sign. A buy rating, however, is no substitute for proof that the shifted revenue actually lands.
The first checkpoint is delivery on the low-end annual revenue target. The bigger test is the announced migration of revenue into 2027. Until Nebius turns expected future income into reported sales, the uncertainty created by the delay will keep weighing on the stock — and no single analyst's price target will resolve it.
Ad
Nebius Stock: New Analysis - 18 November
Fresh Nebius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
